Merrimack Pharmaceuticals To Present Preclinical Research On Five Novel Cancer Therapies
"We are excited about the advancements and research to be presented regarding several of the therapies in Merrimack's robust oncology pipeline," said
Late-Breaking Poster
- Session Title:
Late-Breaking Research - Clinical Research 1
LB-79: Combined treatment with HER3 antibody MM-121/SAR 256212 and EGFR antibody cetuximab in pre-clinical models of head and neck cancerMonday, April 8, 2013 ,1:00 PM - 5:00 PM
Hall A-C, Poster Section 45
Mini-Symposium Presentations
- Session Title: Preclinical and Molecular Endocrinology in Hormone-Responsive Cancers
1072: MM-121/SAR256212 , an anti-ErbB3 antibody, restores sensitivity to letrozole and delays the onset of resistance in an ER+ breast cancer modelSunday, April 7, 2013 ,4:05 PM - 4:20 PM Room 206 ,Washington Convention Center - Session Title: Novel Targeted Therapies 2
4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancerTuesday, April 9, 2013 ,3:05 PM - 3:20 PM Room 152 ,Washington Convention Center
Poster Sessions
- Session Title: Experimental Combination Therapy 1
2077A: MM-141, a novel bispecific antibody co-inhibitor of IGF-1R and ErbB3, inhibits the proliferation of melanoma cellsMonday, April 8, 2013 ,1:00 PM -5:00 PM
Hall A-C, Poster Section 37 - Session Title: Experimental Combination Therapy 2
3271: Tumor priming with cyclophosphamide increases delivery and activity of Her2-targeted liposomal doxorubicin (MM-302) in preclinical models of breast cancerTuesday, April 9, 2013 ,8:00 AM -12:00 PM
Hall A-C, Poster Section 37 - Session Title: Novel Delivery Technologies
5622: The tumor microenvironment modulates the delivery and activation of liposomal encapsulated irinotecan, MM-398Wednesday, April 10, 2013 ,8:00 AM -12:00 PM
Hall A-C, Poster Section 41 - Session Title: Antibody/Protein Therapeutics
5464: In-vitro studies of MM-121/SAR 256212 , an anti-ErbB-3 antibody, in combination with erlotinib in EGFR-wild-type NSCLCWednesday, April 10, 2013 ,8:00 AM -12:00 PM
Hall A-C, Poster Section 36
Sanofi and Merrimack entered into an exclusive, licensing and global collaboration agreement for MM-121 in 2009.
About
Forward-Looking Statement
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
SOURCE
News Provided by Acquire Media